Intercept’s OCA In NASH: When Hitting Surrogate Endpoint Is Not Enough For Accelerated Approval

 
• By Sue Sutter
Tire in mud
The degree to which an effect on a histopathologic surrogate endpoint will ultimately yield benefits 'remains mired in uncertainty.' • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers